With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
亙喜生物賣身阿斯特捷利康 爲中國藥企指引新出路？

The Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant.
亙喜生物專注細胞療法賽道，其進展最快的核心產品仍處於臨牀一期階段，未來將在中、美展開多項臨牀試驗，此舉有望規避現金流不足風險。